Publications by authors named "Jorge Adeva"

Claim this Profile
F
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.
James J Harding, Do-Youn Oh, Teresa Macarulla Mercade, Lipika Goyal, Andreas Varkaris, Jorge Adeva

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer.
Florian Castet, Carles Fabregat-Franco, John Bridgewater, Jin Won Kim, Margherita Rimini, Jorge Adeva

J Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.
Federica Lo Prinzi, Francesca Salani, Silvia Camera, Mario Domenico Rizzato, Anna Saborowski, Jorge Adeva

Int J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Chiara Pirrone, Umberto Malapelle, Francesco Pepe, Federica Lo Prinzi, Federico Nichetti, Jorge Adeva

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population.
Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, Mario Domenico Rizzato, Anna Saborowski, Jorge Adeva

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.
Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, Mario Domenico Rizzato, Anna Saborowski, Jorge Adeva

Int J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025).
Teresa Macarulla, Jorge Adeva, Maria Teresa Cano Osuna, Ana Ruiz Casado, Ana María Jiménez Gordo

Clin Transl Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry.
Carlos López-López, Eva Martínez de Castro, Ana Fernández Montes, Encarnación Jiménez Orozco, Sandra López Peraita, Jorge Adeva

Clin Transl Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.
Francesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, Anna Saborowski, Lorenzo Antonuzzo, Jorge Adeva

Oncology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study.
Alessandro Vitale, Jung Sun Kim, Giuseppe Cabibbo, Andrea Casadei-Gardini, Massimo Iavarone, Jorge Adeva

Liver Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index.
Mara Persano, Margherita Rimini, Francesca Salani, Federica Lo Prinzi, Federico Nichetti, Jorge Adeva

Liver Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe" [The Lancet Regional Health - Europe, volume 50, March 2025, 101170].
Lorenza Rimassa, Angela Lamarca, Grainne M O'Kane, Julien Edeline, Mairéad G McNamara, Jorge Adeva

Lancet Reg Health Eur· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Federica Lo Prinzi, Francesca Salani, Margherita Rimini, Mario Domenico Rizzato, Lorenzo Antonuzzo, Jorge Adeva

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe.
Lorenza Rimassa, Angela Lamarca, Grainne M O'Kane, Julien Edeline, Mairéad G McNamara, Jorge Adeva

Lancet Reg Health Eur· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease.
Anne-Marleen van Keulen, Stefan Buettner, Pim B Olthof, Heinz-Josef Klümpen, Joris I Erdmann, Jorge Adeva

Ann Surg Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, Lorenzo Antonuzzo, Federico Rossari, Jorge Adeva

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Ruth Vera, Carolina Ibarrola-de Andrés, Jorge Adeva, Judith Pérez-Rojas, Pilar García-Alfonso

Rev Esp Patol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Ruth Vera, Carolina Ibarrola-de-Andrés, Jorge Adeva, Judith Pérez-Rojas, Pilar García-Alfonso

Clin Transl Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
Laura Izquierdo-Sanchez, Angela Lamarca, Adelaida La Casta, Stefan Buettner, Kirsten Utpatel, Jorge Adeva

J Hepatol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Andrew X Zhu, Teresa Macarulla, Milind M Javle, R Kate Kelley, Sam J Lubner, Jorge Adeva

JAMA Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REPLY.
Angela Lamarca, Alvaro Santos-Laso, Kirsten Utpatel, Adelaida La Casta, Simone Stock, Jorge Adeva

Hepatology· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Juan W Valle, Arndt Vogel, Crystal S Denlinger, Aiwu Ruth He, Li-Yuan Bai, Jorge Adeva

Lancet Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REPLY.
Angela Lamarca, Alvaro Santos-Laso, Kirsten Utpatel, Adelaida La Casta, Simone Stock, Jorge Adeva

Hepatology· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors.
Edouard Auclin, Perrine Vuagnat, Cristina Smolenschi, Julien Taieb, Jorge Adeva

Cancers (Basel)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread.
Elena Prieto-García, C Vanesa Díaz-García, Alba Agudo-López, Virginia Pardo-Marqués, Inés García-Consuegra, Jorge Adeva

Biomedicines· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis